Iqirvo (elafibranor): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

If your liver had a customer service line, Primary Biliary Cholangitis (PBC) would be one of the top reasons it puts you on hold.
Iqirvo (elafibranor) is a prescription medicine approved for adults with PBC, and it’s designed to help improve certain liver lab markers
linked with the disease. This guide breaks down what Iqirvo is used for, how it’s taken, the most important warnings, common side effects,
and the drug interactions that can turn your medication list into a complicated group chat.

Important: This article is for general education only and is not medical advice. Always follow your prescriber’s directions and ask your pharmacist or clinician about your specific situation.

Quick facts (for busy humans)

• Brand/generic: Iqirvo (elafibranor)
• What it treats: Primary Biliary Cholangitis (PBC) in adults
• How it’s used: With ursodeoxycholic acid/ursodiol (UDCA) if response to UDCA is inadequate, or alone if UDCA can’t be tolerated
• Typical dose: 80 mg by mouth once daily
• Food: Can be taken with or without food
• Big watch-outs: Muscle injury (including rare rhabdomyolysis), fractures, drug-induced liver injury, pregnancy risk, allergic reactions, and avoiding use in complete biliary obstruction
• Interaction “headliners”: Hormonal contraceptives, statins, rifampin, and bile acid sequestrants

What is Iqirvo (elafibranor)?

Iqirvo is a prescription tablet containing elafibranor. It’s approved for adults with Primary Biliary Cholangitis (PBC),
a chronic autoimmune liver disease in which the small bile ducts inside the liver are damaged over time. When bile can’t flow normally,
bile components build up and can contribute to inflammation, scarring, and (in advanced cases) cirrhosis.

Iqirvo’s approved use (indication)

Iqirvo is indicated for the treatment of PBC in adults:
in combination with UDCA in patients who have an inadequate response to UDCA, or
as monotherapy in patients unable to tolerate UDCA.

A quick note on what “accelerated approval” means

Iqirvo received approval based on improvement in a lab-based measure (a biochemical response that includes alkaline phosphatase, or ALP, and bilirubin).
In plain English: the medication demonstrated meaningful changes in certain liver tests associated with PBC. Ongoing (confirmatory) studies are typically used
to verify longer-term clinical benefit. If you’ve ever wished your liver came with a progress bar, ALP is one of the gauges clinicians use.

How Iqirvo works (in plain English)

Elafibranor is a type of medicine called a PPAR agonist. PPARs (peroxisome proliferator-activated receptors) are proteins that influence how the body regulates
inflammation and metabolism. Both elafibranor and its active metabolite interact with multiple PPAR subtypes in lab studies, and their activity may reduce bile acid synthesis.
The exact way this translates into benefit for PBC is not fully understood, but the goal is to improve cholestatic liver lab abnormalities and reduce ongoing injury signals.

Dosing and how to take Iqirvo

Standard dose

The recommended dosage of Iqirvo is 80 mg taken by mouth once daily, with or without food.
Many people pick a consistent time (breakfast, bedtime, “right after I feed the dog”) to make it easier to remember.

Before starting: what your clinician may check

Before initiating Iqirvo, prescribers may:

• Evaluate for muscle pain or myopathy history (because muscle injury is a key safety concern).
• Verify that females of reproductive potential are not pregnant before starting.
• Review liver disease status (especially whether cirrhosis is present and whether there are signs of decompensation).
• Review your medication list for interaction risks (statins, rifampin, hormonal contraception, bile acid sequestrants).

If you take bile acid sequestrants (cholestyramine, colesevelam, colestipol)

Bile acid binding sequestrants can reduce Iqirvo absorption and potentially reduce its effectiveness.
If you use one, take Iqirvo at least 4 hours before or 4 hours after the sequestrant (or as far apart as possible).
This is the medication scheduling version of “keep them separated at recess.”

Missed dose basics

If you miss a dose, follow your prescriber’s instructions or the directions from your pharmacy. A common approach for once-daily medicines is:
take it when you remember the same day, unless it’s close to the next dosethen skip and resume the regular schedule. Do not double up
unless your clinician explicitly tells you to.

Warnings and precautions (the “please read before your liver side-eyes you” section)

1) Myalgia, myopathy, and rhabdomyolysis

Muscle-related side effects can occur, ranging from muscle pain (myalgia) to more serious muscle injury.
In clinical study data, muscle injury included elevated creatine phosphokinase (CPK), myopathy, and rare rhabdomyolysis (sometimes with acute kidney injury).
Risk may increase when Iqirvo is combined with statins.

Call your clinician promptly if you develop new or worsening muscle pain, tenderness, weakness, or dark urineespecially if you also feel unwell.
Clinicians may check CPK and consider pausing or stopping therapy depending on severity and lab results.

2) Fractures

Fractures were observed in clinical trial experience with Iqirvo. Your care team may consider your overall bone health,
especially if you have other fracture risks (age, steroids, low bone density, falls). If you have a fall, persistent bone pain,
or suspected fracture, get evaluated promptly.

3) Pregnancy and fetal/newborn risk

Based on animal data, Iqirvo may cause fetal harm when administered during pregnancy. For females of reproductive potential,
pregnancy testing before treatment is recommended, and effective contraception is important during treatment.

There’s also a key interaction here: Iqirvo may reduce exposure to hormonal contraceptives, which can increase the risk of contraceptive failure.
Many prescribers recommend switching to a non-hormonal method or adding a barrier method while taking Iqirvo and for a period after stopping it.

4) Drug-induced liver injury (DILI)

Drug-induced liver injury has occurred with Iqirvo. Clinicians typically obtain baseline clinical and laboratory assessments at treatment initiation
and monitor thereafter as part of routine management. Treatment may be interrupted if liver tests worsen or if signs and symptoms suggest clinical hepatitis.

Seek medical attention if you develop symptoms that could suggest liver injury such as yellowing of the skin or eyes (jaundice),
right upper abdominal pain, significant fatigue, loss of appetite, or swelling in the legs or abdomen.

5) Hypersensitivity (allergic) reactions

Hypersensitivity reactions can occur. If a severe allergic reaction happens, Iqirvo should be permanently discontinued.
Mild to moderate reactions may require interruption and prompt treatment while symptoms are monitored.
If you develop a rash or other allergic symptoms, contact your healthcare provider right away; seek urgent care for severe symptoms.

6) Biliary obstruction

Avoid use of Iqirvo in patients with complete biliary obstruction. If biliary obstruction is suspected,
Iqirvo may be interrupted while the patient is evaluated and treated as clinically indicated.

7) Decompensated cirrhosis

Use of Iqirvo is not recommended in patients who have or develop decompensated cirrhosis (for example: ascites,
variceal bleeding, or hepatic encephalopathy). Patients with cirrhosis are typically monitored for evidence of decompensation, and clinicians may discontinue
therapy if liver function worsens to moderate or severe hepatic impairment (Child-Pugh B or C).

Side effects: what’s common vs. what’s urgent

Common side effects seen in clinical trials

In clinical trial experience for PBC, the following were among the more commonly reported side effects:

• Weight gain
• Diarrhea
• Abdominal pain
• Nausea and vomiting
• Joint pain (arthralgia)
• Constipation
• Muscle pain
• Fracture
• Gastroesophageal reflux disease (GERD)
• Dry mouth
• Weight loss (yes, both weight gain and weight loss showed uphuman bodies are nothing if not unpredictable)
• Rash

Less common but reported

Additional reactions that occurred more frequently than placebo but in fewer patients included dizziness, gastroenteritis, increased blood creatinine, and anemia.
Gallbladder-related events (new-onset gallstones and cholecystitis) were also reported in a small number of patients.

Side effects that should trigger a call (or urgent care)

• Muscle injury symptoms: new/worsening muscle pain, weakness, severe cramps, dark urine, or feeling very ill.
• Liver injury symptoms: jaundice, right upper abdominal pain, significant fatigue, swelling, loss of appetite, persistent nausea.
• Allergic reaction: rash, hives, swelling, trouble breathing (emergency).
• Biliary obstruction symptoms: jaundice or right upper quadrant painespecially if sudden or severe.
• Suspected fracture: pain, swelling, or inability to bear weight after a fall or injury.

Drug interactions (bring this to your medication list “roll call”)

Drug interactions don’t always mean “never combine.” Often they mean “combine carefully, monitor, and adjust when needed.”
Here are the interactions most emphasized in prescribing information.

Hormonal contraceptives (pill, patch, implant, etc.)

Iqirvo can act as a weak inducer of CYP3A4. Co-administration with hormonal contraceptives may reduce exposure to progestin and ethinyl estradiol,
which may lead to contraceptive failure and/or breakthrough bleeding.

Practical takeaway: clinicians may recommend switching to an effective non-hormonal method or adding a barrier method
during Iqirvo treatment and for at least 3 weeks after the last dose.

Statins (HMG-CoA reductase inhibitors)

Muscle injury (CPK elevation, myalgia, myopathy, rare rhabdomyolysis) has occurred with Iqirvo, and combining Iqirvo with statins can increase the risk of myopathy.
Your clinician may monitor symptoms and consider periodic CPK assessments, especially if you develop muscle complaints.

Example scenario: someone with PBC takes a statin for cholesterol. Adding Iqirvo may mean the care team reviews the statin choice and dose, asks more detailed questions
about muscle symptoms, and sets clearer “call us if…” guidance.

Rifampin

Rifampin can induce drug-metabolizing pathways and may reduce exposure to elafibranor and its active metabolite, potentially delaying or reducing biochemical response.
If rifampin is started while taking Iqirvo, clinicians may monitor ALP and bilirubin more closely to make sure treatment goals are still being met.

Bile acid binding sequestrants

As noted above, bile acid sequestrants may reduce Iqirvo absorption. Separate dosing by at least 4 hours before or after whenever possible.

Other medication considerations

Medication lists can be long, especially in chronic liver disease. Always tell your prescriber and pharmacist about prescription medications,
over-the-counter products, and supplements. If you use multiple specialists, ask one person (often your pharmacist) to be the “med list referee.”

Pictures: what does Iqirvo look like?

Iqirvo is supplied as an 80 mg film-coated tablet. Because many tablets can look similar (and because pill appearance can vary by lot, packaging, and lighting),
do not rely on color alone to identify medication.

How to safely confirm you have the right medication

• Match the name (Iqirvo / elafibranor) and strength (80 mg) on the prescription label.
• Check any imprint information listed by your pharmacy (if applicable).
• If anything looks different than usualnew bottle, new tablet appearance, missing markingsask your pharmacist before taking it.
• Avoid “mystery meds.” Your liver has enough drama; it doesn’t need a plot twist.

How well does Iqirvo work for PBC?

In the main clinical study used for approval, adults with PBC were randomized to Iqirvo 80 mg once daily or placebo. Most participants took background UDCA,
and a smaller number took study drug as monotherapy due to UDCA intolerance.

The primary measure was a biochemical response at Week 52 that included ALP and bilirubin criteria.
In that study, the biochemical response rate was substantially higher with Iqirvo than with placebo, showing that Iqirvo improved key cholestatic lab markers
used to assess PBC activity and treatment response.

Practical monitoring: what your follow-up may look like

PBC management is a marathon, not a sprint, and Iqirvo is usually part of a broader plan. Monitoring commonly includes:

• Liver labs: ALP, bilirubin, ALT/AST as directed by your clinician
• Muscle safety: symptom check-ins and sometimes CPK, especially with muscle complaints or statin use
• Bone health: attention to fracture risk (falls, bone density discussions, vitamin D/calcium guidance when appropriate)
• Medication review: periodic re-check of interactions as medications change

Frequently asked questions

Can Iqirvo replace UDCA?

Some people take Iqirvo with UDCA because UDCA remains a common first-line therapy in PBC. Others use Iqirvo as monotherapy when UDCA isn’t tolerated.
Your prescriber chooses based on prior response, tolerance, and overall liver status.

Will I “feel” it working?

Many benefits are tracked through lab markers like ALP and bilirubin rather than immediate symptom changes. Some people feel better as disease control improves,
while others mainly notice the difference on lab reports. Either way, consistent follow-up matters.

Does it help itching (pruritus)?

Itching in PBC is complicated and may require targeted treatments. While improving cholestasis can help some people over time, itching often needs its own plan
(skin care, trigger management, and prescribed therapies when needed). Ask your clinician for options that fit your case.

Can I drink alcohol while taking Iqirvo?

Alcohol can add extra stress to the liver, and guidance is individualized in liver disease. Rather than guessing, ask your hepatology or GI team what’s safest for you.

Is Iqirvo safe for kids?

Safety and effectiveness have not been established in pediatric patients.

What about breastfeeding?

Because of the potential for serious adverse reactions in a breastfed infant, patients are advised not to breastfeed during treatment and for a period after the last dose.
Discuss timing and alternatives with your clinician.

Experiences with Iqirvo and living with PBC (extra insights, real-world style)

When people talk about “starting a new med,” it often sounds like a single moment: pick up the bottle, take the first tablet, boomnew chapter.
In real life, it’s more like adding a new character to an already busy TV show. You’re not just taking Iqirvo; you’re fitting it into routines, lab schedules,
pharmacy refills, and the ongoing art of “Wait, can I take this with my other thing?”

A common experience in PBC is that progress is measured in labs more than sensations. Someone might say, “I don’t feel dramatically different,
but my ALP is finally moving in the right direction.” That can be emotionally complicated: you want to feel the benefit, not just see it in a portal message.
For some, the win is quietless fatigue over months, fewer flares, a sense of stability. For others, the day-to-day feels the same, and the motivation comes from
knowing the treatment is aimed at protecting the liver long-term.

Another frequent theme is medication logistics. If a person also takes a bile acid sequestrant for itching or cholesterol, the “take it 4 hours apart”
rule can turn the day into a scheduling puzzle. People often solve it by anchoring doses to predictable events: Iqirvo with breakfast, sequestrant with lunch,
and a phone alarm that basically becomes their most reliable friend. The goal isn’t perfectionit’s consistency that’s realistic.

Side effects, when they happen, tend to become their own mini-project. Mild nausea or abdominal discomfort might lead someone to adjust meal timing,
simplify breakfast for a bit, or keep bland snacks around. If reflux shows up, they may talk with a clinician about reflux strategies. If weight changes occur,
people often appreciate a neutral, non-judgmental conversation focused on health rather than blamebecause nobody needs a guilt trip on top of a liver condition.

The muscle warning is one that many people take seriously, especially if they’re also on a statin. In real-world conversations, you’ll hear things like,
“I’m paying more attention to muscle aches than I used to,” or “I learned what CPK is this yearand I didn’t even have to enroll in medical school.”
Clinicians often encourage patients to report new muscle pain promptly, not because most muscle aches are dangerous, but because catching rare problems early is the point.
Some people feel reassured when they have a clear plan: what symptoms matter, which labs might be checked, and when to pause medication.

People also talk about the “human side” of liver disease care: the relief of having more options, the frustration of insurance hurdles, and the comfort of being followed
by a specialist who knows PBC well. Support communities often remind newcomers that it’s normal to feel anxious at the start. The healthiest pattern is usually
a steady one: take the medication as prescribed, keep lab appointments, communicate changes early, and avoid making decisions based on internet horror stories.
(Yes, the internet is great. It’s also where a toaster can be “a fire hazard” and “life-changing” in the same review thread.)

Finally, many people find it empowering to keep a simple one-page “PBC + meds” notecurrent meds, allergies, key warnings, and clinician contact infoespecially for
urgent care visits or travel. It’s not about turning your life into a spreadsheet. It’s about making sure, if you ever need help quickly, you don’t have to rely on memory
while stressed. Your liver already does enough work; it doesn’t need you playing medication detective at 2 a.m.